Skip to main content

Lithium for Suicide Prevention: Umbrella Review and Meta-Analysis

Journal
The American journal of psychiatry (Q1)
Published
18 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Otávio de Lacquila Yano, Giuliana Perrotte, Taeho Greg Rhee, Beatriz Almeida Silva De Thomaz, Vitória Penido de Paula, Jonatas Magalhaes Santos, et al.
PMID
43046292
DOI
10.1176/appi.ajp.20260631

Why clinicians should know about it

  • Picked for Psychiatry and Mental Health (paper of the day, 20 November 2026): Updated randomized evidence on lithium and suicide-related outcomes

Abstract

OBJECTIVE: Lithium has anchored suicide-prevention guidelines for five decades, yet quantitative syntheses of the randomized evidence have produced divergent estimates. The authors evaluated the contemporary randomized evidence on lithium for suicide-related outcomes in patients with psychiatric disorders. METHODS: Five databases were searched from inception to April 6, 2026, for systematic reviews with meta-analyses of randomized trials comparing lithium with placebo, treatment as usual, or active comparators; all eligible trials were re-extracted, with an updated six-source primary-trial search from January 2024. Prespecified outcomes were completed suicide, suicide attempt, deliberate self-harm, all-cause mortality, composite suicide-related events, and treatment discontinuation. The primary estimator was the Mantel-Haenszel odds ratio without continuity correction, and certainty of evidence was rated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. RESULTS: Ten systematic reviews, one reanalysis, and 20 trial publications (22 strata; 3,675 participants) were included. For completed suicide (11 informative comparisons, 2,292 participants; six events with lithium vs. 16 with comparators), the pooled estimate favored lithium but included the null (odds ratio [OR]=0.39, 95% CI=0.15, 1.00; I²=0%). A Peto sensitivity estimate reached statistical significance (OR=0.42, 95% CI=0.18, 0.98), whereas excluding the most influential comparison attenuated the estimate (OR=0.43, 95% CI=0.13, 1.40). In exploratory subgroup analysis, the signal concentrated in trials enrolling mixed mood-disorder populations (four trials; OR=0.25, 95% CI=0.07, 0.90). Treatment discontinuation favored lithium over placebo but active comparators over lithium. No significant effects emerged for suicide attempt, deliberate self-harm, all-cause mortality, or composite suicide-related events. GRADE certainty was low to very low. CONCLUSIONS: Current evidence indicates greater uncertainty than suggested by earlier syntheses, with a sparse completed-suicide signal that was estimator-sensitive and with no consistent evidence across related outcomes. Lithium remains a treatment option when clinically indicated, but adequately powered pragmatic trials that prespecify suicidal behavior and balance clinical contact between arms are needed.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.